• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncotelic Therapeutcs Inc (OP:OTLC)

0.0372 UNCHANGED
Streaming Delayed Price Updated: 2:52 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0372
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0372
Today's Range 0.0372 - 0.0372
52wk Range 0.0150 - 0.1100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Preclinical Data Supporting IV Cancer Therapy
July 22, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Brings AI and Robotics Together in New Platform
July 15, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property

Performance

YTD
-52.2%
-52.2%
1 Month
-25.6%
-25.6%
3 Month
+3.0%
+3.0%
6 Month
-51.4%
-51.4%
1 Year
-26.3%
-26.3%

More News

Read More
Oncotelic Therapeutics Inc. (OTLC) Targets Biotech’s Manufacturing Bottleneck with AI-Powered GMP Platform
July 09, 2026
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Positive Safety Review for Phase 1b Sapu003 Trial
July 07, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform
June 29, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Eyes Opportunity Through AI and Pharmaceutical Automation
June 24, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation
June 23, 2026
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Launches AI-Powered GMP Manufacturing Services Platform at BIO 2026
June 18, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
AINewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Advances Robotics Deployment at SAPU Bio Sterile Manufacturing Facility
June 17, 2026
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI-Powered GMP Manufacturing Platform
June 17, 2026
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026
June 08, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation
June 05, 2026
Via Investor Brand Network
Topics Artificial Intelligence
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Advanced Cancer Drug Delivery
June 05, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
June 05, 2026
From NetworkNewsWire
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Drug-Delivery Market Growth
June 04, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
June 04, 2026
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Sapu003 Phase 1b Program, Appoints Global CRO for International Study Execution
June 03, 2026
Via Investor Brand Network
Topics Intellectual Property
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
June 03, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
From BioMedWire
Via GlobeNewswire
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies
June 02, 2026
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies
June 02, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
June 02, 2026
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
June 01, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
Via Investor Brand Network

Frequently Asked Questions

Is Oncotelic Therapeutcs Inc publicly traded?
Yes, Oncotelic Therapeutcs Inc is publicly traded.
What exchange does Oncotelic Therapeutcs Inc trade on?
Oncotelic Therapeutcs Inc trades on the OTC Traded
What is the ticker symbol for Oncotelic Therapeutcs Inc?
The ticker symbol for Oncotelic Therapeutcs Inc is OTLC on the OTC Traded
What is the current price of Oncotelic Therapeutcs Inc?
The current price of Oncotelic Therapeutcs Inc is 0.0372
When was Oncotelic Therapeutcs Inc last traded?
The last trade of Oncotelic Therapeutcs Inc was at 07/22/26 02:52 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap